Eastgate Biotech (ETBI) 10-K 2 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Apr. 01, 2013
Document and Entity Information:	'	'
Entity Registrant Name	'EASTGATE ACQUISITIONS CORP	'
Document Type	'10-K	'
Document Period End Date	31-Dec-13	'
Amendment Flag	'false	'
Entity Central Index Key	'0001099574	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	43,729,628
Entity Public Float	'	$43,799,628
Entity Filer Category	'Smaller Reporting Company	'
Entity Current Reporting Status	'No	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'FY	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$458	$100,000
Prepaid Assets	'	4,500
Total Current Assets	458	104,500
PROPERTY & EQUIPMENT, net	71,297	'
Total Long Term Assets	71,297	'
TOTAL ASSETS	71,755	104,500
Accounts payable	421,439	229,250
Accrued liabilities related party	960,000	'
Capital lease obligation	24,380	'
Accrued interest - related parties	95,004	35,155
Notes payable - related parties	898,109	449,103
Total Current Liabilities	2,398,932	713,508
Common stock;100,000,000 shares authorized, at $0.00001 par value, 31,625,000 and 31,625,000 shares issued and outstanding, respectively	316	316
Additional paid-in capital	134,884	134,884
Subscription payable	2,000	'
Accumulated other comprehensive income	147	'
Deficit accumulated during the development stage	-2,464,524	-744,208
Total Stockholders' Deficit	-2,327,177	-609,008
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$71,755	$104,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended		172 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
REVENUES	'	'	'
Professional fees	$52,524	$116,874	$169,398
Research and development	132,092	105,422	237,514
General and administrative	1,445,912	383,501	1,933,611
Marketing and selling	25,554	'	25,554
Total Operating Expenses	1,656,082	605,797	2,366,077
LOSS FROM OPERATIONS	-1,656,082	-605,797	-2,366,077
Interest expense	-64,234	-17,023	-98,447
Total Other Expense	-64,234	-17,023	-98,447
LOSS BEFORE INCOME TAXES	-1,720,316	-622,820	-2,464,524
COMPREHENSIVE LOSS	-1,720,316	-622,820	-2,464,524
BASIC LOSS PER SHARE	($0.05)	($0.03)	'
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	'	23,865,437	'
OTHER COMPREHENSIVE INCOME	-1,720,316	-622,820	-2,464,524
Other Comprehensive Income	147	'	147
Total Comprehensive Loss	($1,720,169)	($622,820)	($2,464,377)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		172 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
OPERATING ACTIVITIES	'	'	'
Profit (loss)	($1,720,316)	($622,820)	($2,464,524)
Expenses paid on the Company's behalf by a related party	81,584	339,513	480,687
Common stock issued for services	'	50,000	50,000
Depreciation	14,519	'	14,519
Services contributed by shareholders	'	3,000	34,700
Change in accrued interest	59,849	17,965	95,004
Change in prepaid asset	4,500	-4,500	'
Change in accounts payable	192,189	216,842	421,439
Change in accrued liabilities related party	960,000	'	960,000
Net cash used in Operating Activities	-407,675	'	-408,175
Purchase of property and equipment	-22,273	'	-22,273
Net Cash Used in Investing Activities	-22,273	'	-22,273
Payments on capital lease obligation	-39,163	'	-39,163
Proceeds from notes payable to related parties	367,422	100,000	467,422
Proceeds from subscription payable	2,000	'	2,000
Common stock issued for cash	'	'	500
Net Cash Provided (used in) by Financing Activities	330,259	100,000	430,759
NET INCREASE (DECREASE) IN CASH	-99,689	100,000	311
Effect of foreign currency translation adjustments	147	'	147
CASH AT BEGINNING OF PERIOD	100,000	'	'
CASH AT END OF PERIOD	458	100,000	458
Interest	4,386	'	4,386
Capital contribution by officer - payment of related party payable on behalf of company	'	50,000	50,000
Property & equipment purchased under capital lease obligation	$63,543	'	$63,543

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Common stock	Additional Paid In Capital	Subscriptions Payable	Accumulated other comprehensive income	Accumulated Deficit	Total
Stockholders' Equity, beginning balance at Sep. 07, 1999	'	'	'	'	'	'
Common stock issued for cash, value	$116	$384	'	'	'	$500
Common stock issued for cash, shares	11,625,000	'	'	'	'	11,625,000
Stockholders' Equity, ending balance at Dec. 31, 1999	116	384	'	'	'	500
Balance common shares, ending balance at Dec. 31, 1999	11,625,000	'	'	'	'	11,625,000
NET LOSS	'	'	'	'	-3,320	-3,320
Stockholders' Equity, ending balance at Dec. 31, 2004	116	384	'	'	-3,320	-2,820
Balance common shares, ending balance at Dec. 31, 2004	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	500	'	'	'	500
NET LOSS	'	'	'	'	-600	-600
Stockholders' Equity, ending balance at Dec. 31, 2005	116	884	'	'	-3,920	-2,920
Balance common shares, ending balance at Dec. 31, 2005	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	1,700	'	'	'	1,700
NET LOSS	'	'	'	'	-5,555	-5,555
Stockholders' Equity, ending balance at Dec. 31, 2006	116	2,584	'	'	-9,475	-6,775
Balance common shares, ending balance at Dec. 31, 2006	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	5,500	'	'	'	5,500
NET LOSS	'	'	'	'	-9,681	-9,681
Stockholders' Equity, ending balance at Dec. 31, 2007	116	8,084	'	'	-19,156	-10,956
Balance common shares, ending balance at Dec. 31, 2007	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	6,000	'	'	'	6,000
NET LOSS	'	'	'	'	-24,309	-24,309
Stockholders' Equity, ending balance at Dec. 31, 2008	116	14,084	'	'	-43,465	-29,265
Balance common shares, ending balance at Dec. 31, 2008	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	6,000	'	'	'	6,000
NET LOSS	'	'	'	'	-23,649	-23,649
Stockholders' Equity, ending balance at Dec. 31, 2009	15	20,084	'	'	-67,114	-46,914
Balance common shares, ending balance at Dec. 31, 2009	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	6,000	'	'	'	6,000
NET LOSS	'	'	'	'	-24,354	-24,354
Stockholders' Equity, ending balance at Dec. 31, 2010	116	26,084	'	'	-91,468	-65,268
Balance common shares, ending balance at Dec. 31, 2010	11,625,000	'	'	'	'	11,625,000
Contribution of services, value	'	6,000	'	'	'	6,000
NET LOSS	'	'	'	'	-29,920	-29,920
Stockholders' Equity, ending balance at Dec. 31, 2011	116	32,084	'	'	-121,388	-89,188
Balance common shares, ending balance at Dec. 31, 2011	11,625,000	'	'	'	'	11,625,000
Common stock issued for services, value	200	99,800	'	'	'	100,000
Common stock issued for services, shares	20,000,000	'	'	'	'	20,000,000
Contribution of services, value	'	3,000	'	'	'	3,000
NET LOSS	'	'	'	'	-622,820	-622,820
Stockholders' Equity, ending balance at Dec. 31, 2012	316	134,884	'	'	-744,208	-609,008
Balance common shares, ending balance at Dec. 31, 2012	31,625,000	'	'	'	'	31,625,000
Translation adjustment	'	'	'	147	'	147
NET LOSS	'	'	'	'	-1,720,316	-1,720,316
Stockholders' Equity, ending balance at Dec. 31, 2013	316	134,884	2,000	147	-2,464,524	-2,327,177
Subscription payable at Dec. 31, 2013	'	'	$2,000	'	'	$2,000
Balance common shares, ending balance at Dec. 31, 2013	31,625,000	'	'	'	'	31,625,000

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 1 - Summary of Significant Accounting Policies	'
	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Business
	Eastgate Acquisitions Corporation (The Company) was organized on September 8, 1999, under the laws of the State of Nevada. The Company is a development stage company which has limited history of operations is engaged in the research and development of drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules.  During the year ended December 31, 2012 the Company formed Eastgate Pharmaceuticals, Inc. as a wholly-owned subsidiary of the Company.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Eastgate Acquisitions Corporation and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
	Development Stage Company
	The accompanying consolidated financial statements have been prepared in accordance with the provision of FASB ASC Topic 915, Development Stage Entities.”
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
	Property and Equipment
	Property and equipment are recorded at cost and are depreciated when placed into service using the straight-line method based on their estimated useful lives of five year. Equipment under capital leases are stated at the lower of fair market value or net present value of the minimum lease payments at the inception of the leases.
	Research and Development Costs
	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.
	Impairment of Long-Lived Assets
	The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
	Income Taxes
	The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 39% to net the loss before provision for income taxes for the following reasons:
			December 31,		December 31,
			2013		2012
	Income tax expense at statutory rate	$	-670,860	$	-242,900
	Contributed services				1,170
	Stock issued for services				39,000
	Depreciation and amortization		5,662
	Change in valuation allowance		665,198		202,730
	Income tax expense per books	$	-0-	$	-0-
	Net deferred tax assets consist of the following components as of:
			December 31,		December 31,
			2013		2012
	NOL carryover	$	961,102	$	290,241
	Valuation allowance		-961,102		-290,241
	Net deferred tax asset	$	-0-	$	-0-
	Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $2,322,844 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.
	Earnings (Loss) per Share
	The Company has adopted ASC 260, “Earnings Per Share,” (“EPS”) which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures, and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.
	The Company has no potentially dilutive securities, such as options or warrants, currently issued and outstanding.
	Comprehensive Loss
	Other comprehensive loss, which includes only foreign currency translation adjustments, is shown in the Statement of Changes in Stockholder’s Equity.
	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period.  Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period.  Translation adjustments that arise from translating the foreign subsidiary’s financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders’ equity.
	Recent Accounting Pronouncements
	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is not expected to have a material impact on the Company’s financial position or statements.
	Accounting Basis
	The basis is accounting principles generally accepted in the United States of America.  The Company has adopted a December 31 fiscal year end.

Note_2_Going_Concern

Note 2 - Going Concern	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 2 - Going Concern	'
	NOTE 2 - GOING CONCERN
	The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern.  However, the Company has accumulated deficit of $2,464,524 as of December 31, 2013.  The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time, raising substantial doubt about its ability to continue as a going concern.
	Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

Note_3_Relatedparty_Transactio

Note 3 - Related-party Transactions	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 3 - Related-party Transactions	'
	NOTE 3 - RELATED-PARTY TRANSACTIONS
	Notes payable – related parties
	The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet. The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum, are unsecured and are due and payable upon demand.
	-          During the years ended December 2013 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have paid for expenses on behalf of the Company of $81,584 and advanced cash to the Company of $367,422, As of December 31, 2012 they paid for expenses on behalf of the Company of $339,513 and advanced cash to the Company of $100,000.  As of December 31, 2013 and 2012, the Company owes $95,004 and $35,155 of accrued interest to related parties, respectively, resulting from interest expense of $59,848 and $17,965, respectively.
	-          During 2012 in connection with the a agreement to purchase patents from a related party, an officer and director of the Company agreed to pay $50,000 to a former officer thus reducing the amount owed to that former officer by $50,000. As consideration to the officer and director for this $50,000 payment on behalf of the Company, 10,000,000 shares of common stock were issued to the officer and director. The amount for patents purchased valued at $0 and the related party debt paid by the officer of $50,000 and has been recorded as contributed capital in equity (See Note 6).
	Officer Compensation
	During the year ended December 31, 2012, the former CEO contributed various administrative services to the Company. These services include basic management and accounting services and utilization of office space and equipment and were recorded as contributed capital of $3,000 for the year ended December 31, 2012.  In the last 6 months of 2012 the Company has a new CEO who personally financed most of the operations to December 31, 2013.  In the year ended December 31, 2012 the Company did not record any compensation for the new CEO.  In the year ended December 31, 2013 the Company recorded compensation expense of $216,000 which is recorded in accrued liabilities related party.  In addition, services provided by other officers and management of the Company amounting to an expense of $744,000 was recorded in accrued liabilities related party.

Note_4_Property_Equipment_and_

Note 4 - Property & Equipment and Capital Lease Obligation	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 4 - Property & Equipment and Capital Lease Obligation	'
	NOTE 4 – PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION
	On January 4, 2013 the Company entered into a capital lease agreement to purchase equipment. The lease has a term of 19 months starting January 4, 2013 with the final payment due on August 1, 2014. The lease specifies a monthly rate of $3,600. The lease requires minimum lease payments of $68,400 over the term of the lease. The lease was initially recorded at $63,543, which is the present value of the minimum lease payments (less no executor cost) using the Company’s incremental borrowing rate of 10%. During the twelve months ended December 31, 2013 the Company paid principal of $39,163 ($0 during 2012) against the capital lease obligation and corresponding interest of $4,037, leaving an amount owing at the end of the period of $24,380 ($0 at December 31, 2012), $0 of which is a long-term obligation.
	Pursuant to ASC 840-30 for capital leases, the equipment was recorded at the same value as the initial capital lease obligation of $63,543. Also during the twelve months ending December 31, 2013, the Company purchased additional equipment for cash of $22,273. The estimated useful life of all equipment purchased during the year ended December 31, 2013 is 5 years. Depreciation expense of $14,519 and $0 was recorded during the year ended December 31, 2013 and December 31, 2012, respectively, which leaves a net balance in Property & Equipment of $71,297 and $0 at December 31, 2013 and December 31, 2012, respectively.
	The costs and accumulated depreciation of property and equipment are summarized as follows:
			December 31,		December 31,
			2013		2012
	Lab Equipment	$	85,816	$	-0-
	Less: Accumulated Depreciation		-14,519		-0-
	Property and Equipment, Net	$	71,297	$	-0-
	Depreciation expense amounted to $14,519 and $0 for the years ended December 31, 2013 and 2012, respectively.

Note_5_Commitments_and_Conting

Note 5 - Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 5 - Commitments and Contingent Liabilities	'
	NOTE 5 – COMMITMENTS AND CONTINGENT LIABILITIES
	Operating Lease
	The Company has assumed a lease agreement from a company controlled by the CEO on October 31, 2012 for the use of operating space owned by a third party, which expires on May 16, 2017.
	Aggregate minimum annual lease commitments of the Company under non-cancelable operating leases as of December 31, 2013 are as follows:
			Year Amount
	2014	$	66,619
	2015		68,400
	2016		68,400
	2017		28,500
	Thereafter		0
	Total Minimum Lease Payments	$	231,919
	Lease expense amounted to $69,984, $14,963 and $0 for the years ended December 31, 2013, 2012 and 2011, respectively.
	The preceding data reflects existing leases and does not include replacements upon their expiration.  In the normal course of business, operating leases are generally renewed or replaced by other leases.
	Capital Lease
	The Company has entered into capital lease agreement for the use of laboratory equipment.
	The last payment for this lease will be July 1, 2014.  Total payments during 2014 will be $25,200
	Lease expense amounted to $39,163 and $0 for the years ended December 31, 2013 and 2012, respectively.

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 6 - Stockholders' Equity	'
	NOTE 6 – STOCKHOLDERS’ EQUITY
	During the years ended December 31, 2013 and 2012, an officer of the Company has contributed various administrative services to the Company. These services include basic management and accounting services, and utilization of office space and equipment. These services have been valued at $500 per month of service and have been recorded as capital contributions of $-0- and $3,000 as of the periods ending December 31, 2013 and December 31, 2012, respectively.  In May 2012 the CEO left the Company.  The new CEO’s compensation is documented in Note 3.
	As stated above in Note 3, on May 22, 2012 pursuant to a patent acquisition agreement, the Company issued 10,000,000 shares of common stock valued at $0.005 per share to a Company officer in exchange for patent rights contributed, and forgiveness of debt to a related party of $50,000.  Also pursuant to the patent acquisition agreement, the Company issued an additional 10,000,000 shares of common stock to a third party in exchange for services, valued also at $0.005 per share.
	Subscription Payable
	In December 2013 the Company received a deposit of $2,000 for the purchase of the Company’s common stock.  The Board approved this issue in March 2014.

Note_7_Subsequent_Events

Note 7 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Notes	'
Note 7 - Subsequent Events	'
	NOTE 7 - SUBSEQUENT EVENTS
	In accordance with ASC 855 Company management reviewed all material events through the date of this report.
	In March 2014, the Company completed private placement transaction with certain investors that resulted in $1,037,500 in net proceeds to the Company.  Pursuant to the terms of the transaction, the Company sold 4,640,000 Units, each consisting of one share of our common stock and 0.75 warrants to purchase one share of our common stock at $0.25 per share exercisable for a period of five years.  Each Unit was priced at $0.25 per Unit.  The Company issued a total of 4,640,000 shares and 3,480,000 five year warrants as a result of this transaction.   The Company paid $110,000 and issued 1,000,000 shares of our common stock, valued at $250,000 to Chardan Capital Markets, LLC as commissions for their services in connection with this transaction.
	On March 14, 2014, our Board of Directors approved an offer to convert $1,165,000 of accrued liabilities to 4,660,000 Units at $0.25 per Unit.  Each Unit consists of one share of our common stock and 0.75 warrants to purchase one share of our common stock at $0.25 per share exercisable for a period of five years from the date of the grant.  Included in this amount of accrued liabilities is $960,000 in deferred executive compensation due to executives and directors of the company.
	On March 21, 2014, our Board of Directors approved an offer to convert $80,410 of accounts payable to 321,628 shares of our common stock at $0.25 per share.
	On March 21, 2014, our Board of Directors ratified the issuance of 1,553,000 shares of our common stock to our consultants and advisors for services rendered.  The shares were valued at $0.25 per share, or $388,266. for the purposes of this transaction

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies: Nature of Business (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Nature of Business	'
	Nature of Business
	Eastgate Acquisitions Corporation (The Company) was organized on September 8, 1999, under the laws of the State of Nevada. The Company is a development stage company which has limited history of operations is engaged in the research and development of drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules.  During the year ended December 31, 2012 the Company formed Eastgate Pharmaceuticals, Inc. as a wholly-owned subsidiary of the Company.

Note_1_Summary_of_Significant_2

Note 1 - Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Eastgate Acquisitions Corporation and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

Note_1_Summary_of_Significant_3

Note 1 - Summary of Significant Accounting Policies: Development Stage Company (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Development Stage Company	'
	Development Stage Company
	The accompanying consolidated financial statements have been prepared in accordance with the provision of FASB ASC Topic 915, Development Stage Entities.”

Note_1_Summary_of_Significant_4

Note 1 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note_1_Summary_of_Significant_5

Note 1 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

Note_1_Summary_of_Significant_6

Note 1 - Summary of Significant Accounting Policies: Research and Development Costs (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Research and Development Costs	'
	Research and Development Costs
	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.

Note_1_Summary_of_Significant_7

Note 1 - Summary of Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Impairment of Long-lived Assets	'
	Impairment of Long-Lived Assets
	The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Note_1_Summary_of_Significant_8

Note 1 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Income Taxes	'
	Income Taxes
	The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 39% to net the loss before provision for income taxes for the following reasons:
			December 31,		December 31,
			2013		2012
	Income tax expense at statutory rate	$	-670,860	$	-242,900
	Contributed services				1,170
	Stock issued for services				39,000
	Depreciation and amortization		5,662
	Change in valuation allowance		665,198		202,730
	Income tax expense per books	$	-0-	$	-0-
	Net deferred tax assets consist of the following components as of:
			December 31,		December 31,
			2013		2012
	NOL carryover	$	961,102	$	290,241
	Valuation allowance		-961,102		-290,241
	Net deferred tax asset	$	-0-	$	-0-
	Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $2,322,844 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.

Note_1_Summary_of_Significant_9

Note 1 - Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Earnings (loss) Per Share	'
	Earnings (Loss) per Share
	The Company has adopted ASC 260, “Earnings Per Share,” (“EPS”) which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures, and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.
	The Company has no potentially dilutive securities, such as options or warrants, currently issued and outstanding.

Recovered_Sheet1

Note 1 - Summary of Significant Accounting Policies: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Comprehensive Loss	'
	Comprehensive Loss
	Other comprehensive loss, which includes only foreign currency translation adjustments, is shown in the Statement of Changes in Stockholder’s Equity.

Recovered_Sheet2

Note 1 - Summary of Significant Accounting Policies: Foreign Currency Translation (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Foreign Currency Translation	'
	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period.  Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period.  Translation adjustments that arise from translating the foreign subsidiary’s financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders’ equity.

Recovered_Sheet3

Note 1 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is not expected to have a material impact on the Company’s financial position or statements.

Recovered_Sheet4

Note 1 - Summary of Significant Accounting Policies: Accounting Basis (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Accounting Basis	'
	Accounting Basis
	The basis is accounting principles generally accepted in the United States of America.  The Company has adopted a December 31 fiscal year end.